FINANCIAL STATEMENT RESTATEMENT (Tables)

9 Months Ended

Jul. 31, 2025

Accounting Changes and Error Corrections [Abstract]

Schedule of statement of operations

Statement of Operations for the three months ended July 31, 2024	As Previously Reported			Adjustment			As Restated
Depreciation and amortization	$	49,964		$	(1,037	)	$	48,927
Total Operating Expenses	$	490,250		$	(1,037	)	$	489,213
Loss from Operations	$	(496,621	)	$	1,037		$	(495,584	)
Net Loss	$	(496,621	)	$	1,037		$	(495,584	)
PER SHARE AMOUNTS
Basic and diluted net loss per share	$	(0.00	)	$	—		$	(0.00	)
Weighted average number of common shares outstanding - basic and diluted		410,591,730			—			410,591,730

Statement of Operations for the nine months ended July 31, 2024	As Previously Reported			Adjustment			As Restated
Operating expenses
General and administrative expenses	$	1,440,197		$	(18,864	)	$	1,421,333
Depreciation and amortization	$	120,056		$	7,938		$	127,994
Total Operating Expenses	$	1,569,846		$	(10,926	)	$	1,558,920
Loss from Operations	$	(1,584,438	)	$	10,926		$	(1,573,512	)
Net Loss	$	(1,584,438	)	$	10,926		$	(1,573,512	)
PER SHARE AMOUNTS
Basic and diluted net loss per share	$	(0.00	)	$	—		$	(0.00	)
Weighted average number of common shares outstanding - basic and diluted		416,515,952			—			416,515,952

Schedule of statement of changes in stockholders’ deficit

Changes in Statement of Stockholders' Deficit for the three months ended July 31, 2024	As Previously Reported			Adjustment			As Restated
Beginning Additional Paid-in Capital - Balance at April 30, 2024	$	41,291,591		$	390,275		$	41,681,866
Beginning Accumulated Deficit - Balance at April 30, 2024	$	(42,697,762	)	$	(476,270	)	$	(43,174,032	)
Beginning Total Stockholders' Deficit - Balance at April 30, 2024	$	(920,868	)	$	(90,995	)	$	(1,011,863	)
Series A preferred issued pursuant to patent agreement, shares		10,000,000			(5,000,000	)		5,000,000
Series A preferred issued pursuant to patent agreement, amount	$	10,000		$	(5,000	)	$	5,000
Net loss for the three months ended July 31, 2024	$	(496,621	)	$	1,037		$	(495,584	)
Ending Additional paid in capital - Balance at July 31, 2024	$	41,784,933		$	390,275		$	42,175,208
Ending Accumulated Deficit - Balance at July 31, 2024	$	(43,194,383	)	$	(475,233	)	$	(43,669,616	)
Ending Total Stockholders' Deficit - Balance at July 31, 2024	$	(984,711	)	$	(89,958	)	$	(1,074,669	)

Changes in Statement of Stockholders' Deficit for the nine months ended July 31, 2024	As Previously Reported			Adjustment			As Restated
Beginning Additional Paid-in Capital - Balance at October 31, 2023	$	41,079,902		$	390,275		$	41,470,177
Beginning Accumulated Deficit - Balance at October 31, 2023	$	(41,609,945	)	$	(486,159	)	$	(42,096,104	)
Beginning Total Stockholders' Deficit - Balance at October 31, 2023	$	(92,201	)		(100,884	)		(193,085	)
Series A preferred issued pursuant to patent agreement, shares		10,000,000			(5,000,000	)		5,000,000
Series A preferred issued pursuant to patent agreement, amount	$	10,000		$	(5,000	)	$	5,000
Net loss for the nine months ended July 31, 2024	$	1,584,438		$	(10,926	)	$	1,573,512
Ending Additional paid in capital - Balance at July 31, 2024	$	41,784,933		$	390,275		$	42,175,208
Ending Accumulated Deficit - Balance at July 31, 2024	$	(43,194,383	)	$	(475,233	)	$	(43,669,616	)
Ending Total Stockholders' Deficit - Balance at July 31, 2024	$	(984,711	)	$	(89,958	)	$	(1,074,669	)

Schedule of statement of cash flows

Statement of Cash Flows for the nine months ended July 31, 2024	As Previously Reported			Adjustment			As Restated
Cash Flow from Operating Activities
Net loss	$	(1,584,438	)	$	10,926		$	(1,573,512	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$	120,056		$	7,938		$	127,994
Changes in operating assets and liabilities:
Increase/(Decrease) in accounts payable	$	21,127		$	(21,560	)	$	(433	)
Operating lease ROU assets and lease liabilities, net	$	844		$	146		$	990
Net Cash Used in Operating Activities	$	(1,380,178	)	$	(2,550	)	$	(1,382,728	)
Cash Flows from Investing Activities
Purchase of property and equipment	$	(32,904	)	$	2,550		$	(30,354	)
Net Cash Used in Investing Activities	$	(368,676	)	$	2,550		$	(366,126	)
Net increase (decrease) in cash	$	(156,242	)	$	—		$	(156,242	)
Cash at beginning of period	$	235,159		$	—		$	235,159
Cash at end of period	$	78,917		$	—		$	78,917
Supplemental Disclosure for Non-Cash Investing and Financing Activities:
Record right-to-use asset and lease liability per ASC 842	$	(135,875	)	$	(31,874)		$	(167,749	)